Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover Trials

@article{Pereira2005AreBA,
  title={Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover Trials},
  author={J. Pereira and A. Holbrook and L. Dolovich and C. Goldsmith and L. Thabane and J. Douketis and M. Crowther and S. Bates and Jeffrey S. Ginsberg},
  journal={Annals of Pharmacotherapy},
  year={2005},
  volume={39},
  pages={1188 - 1193}
}
BACKGROUND Warfarin is a commonly used anticoagulant in North America. Several generic formulations have been approved, raising concern over the safety and efficacy of these products compared with brand-name Coumadin. OBJECTIVE To ensure that generic warfarin products can be safely interchanged with Coumadin. METHODS Multiple n-of-1 randomized, double-blind, crossover trials switched outpatients (N = 7) between a generic warfarin formulation (Apo-warfarin) and Coumadin over 30 weeks. Study… Expand
Brand Name versus Generic Warfarin: A Systematic Review of the Literature
TLDR
The results of a systematic review of the literature suggest that generic warfarin products may be as safe and effective as brand name products and that patients may be safely treated with these products. Expand
Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial
TLDR
Marevan and União Química warfarin had equivalent therapeutic effectiveness and both could be confidently used for anticoagulation and the comparison between Marevan and TW was inconclusive and does not warrant a statement of equivalence. Expand
Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil
TLDR
The WARFA trial is the first comparison of the more readily applicable INR results between branded and generic warfarins in Brazil and is important because warfarin are commonly switched between in the course of a chronic treatment in Brazil. Expand
Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients
  • Rishi J. Desai, C. Gopalakrishnan, +7 authors Joshua J. Gagne
  • Medicine
  • Clinical pharmacology and therapeutics
  • 2019
TLDR
Results from subgroup analyses of patients with atrial fibrillation, CHADS‐VASc score ≥3, and HAS‐BLED score ≥ 3 were consistent with the primary analysis, and hazard ratios comparing brand vs. generic warfarin initiators for the effectiveness, safety, and all‐cause mortality outcomes were consistent. Expand
Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis
TLDR
The evidence is insufficient and too heterogeneous to draw any firm conclusion regarding the effectiveness and safety of generic drugs in cardiology, however, the crude risk of hospital visits was higher for patients exposed to generic compared to brand-name cardiovascular drugs. Expand
Generic versus brand-name drugs used in cardiovascular diseases
TLDR
The evidence for clinical equivalence between brand-name and generic cardiovascular drugs is strengthened, and Physicians could be reassured about prescribingGeneric cardiovascular drugs, and health care organization about endorsing their wider use. Expand
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.
TLDR
Clinical evidence does not support the notion that brand-name drugs used in cardiovascular disease are superior to generic drugs, and a substantial number of editorials counsel against the interchangeability of generic drugs. Expand
Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States
TLDR
Predict and compare the lifetime cost‐effectiveness of brand dabigatran with hypothetical future generics showed that generic dabig atran with lower‐than‐brand systemic exposure were dominant and generics with extremely high systemic exposure was not cost‐effective compared with the brand reference. Expand
GENERICS : NEED FOR CLINICAL CONCERN ?
TLDR
In this case, switchability rather than prescribability may cause problems, and low pharmaceutical quality is more frequent when drugs are produced in certain countries, in some cases causing a real concern when activity and safety are considered. Expand
Improved Stability in INR with Coumadin for a Patient Requiring Very Low Warfarin Doses
TLDR
Patients who require very low warfarin dosages to consistently maintain therapeutic anticoagulation may experience less therapeutic stability while on a generic product. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 23 REFERENCES
Are All Warfarin Preparations Alike? A Comprehensive Overview of Current Data, Emerging Opinions, and Perspectives
TLDR
The issues surrounding the substitution of generic warfarin sodium for brand warFarin sodium (Coumadin), and whether consistent and safe anticoagulation can be maintained if these products are interchanged are discussed. Expand
Observational cohort study of switching warfarin sodium products in a managed care organization.
  • C. Swenson, G. Fundak
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2000
TLDR
The effectiveness and safety of switching warfarin sodium products in a cohort of patients at a managed care organization were studied and the variability of the INR in patients in the conversion group was not significantly different after the switch. Expand
Generic Warfarin: Implications for Patient Care—Another View
TLDR
It is believed that this article contains a number of incorrect conclusions that are based on inaccurate interpretation of data and is important to provide a more complete and accurate discussion and interpretation of the issues. Expand
Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
  • S. Walker, M. Friesen
  • Medicine
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 1999
TLDR
A computer simulation indicates that two bioequivalent (vs. reference) generic warfarin products may not be bioequivalence to each other. Expand
Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.
TLDR
A computer simulation was conducted to determine the likelihood of two bioequivalent generic warfarin formulations (with varying bioavailability) passing current bioequivalence criteria against each other at varying bio availability. Expand
Controlled trials in single subjects. 1. Value in clinical medicine.
Randomised controlled group trials are the gold standard in clinical research and provide information about the average effect of a treatment in a target population. Such information, however, cannotExpand
Controlled trials in single subjects: Author's reply
TLDR
The question then arises whether an individual doctor would not be wiser to base his decision on what to prescribe on the averages reported from conventional clinical trials rather than on the individual results from an n of 1 trial. Expand
Bioequivalence and interchangeability of narrow therapeutic range drugs. Canadian Society for Pharmaceutical Sciences discussion.
  • E. Palylyk-Colwell, F. Jamali, +10 authors G. Zhanel
  • Medicine
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 1998
A Canadian Society for Pharmaceutical Sciences (CSPS) discussion group was held on August 23, 1997 in Edmonton, Alberta to discuss issues surrounding the bioequivalence of narrow therapeutic rangeExpand
Economic evaluation alongside n-of-1 trials: getting closer to the margin.
TLDR
The issues around the use of economic n-of-1 trials with a hypothetical example are illustrated, and their potential for the estimation of individualized cost-effectiveness is discussed. Expand
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
TLDR
The mainstay treatment for atrial fibrillation is Coumadin Aspirin Reinfarction, but the use of aspirin for other reasons is also being considered. Expand
...
1
2
3
...